| Drug Name |
Niraparib |
| Drug ID |
BADD_D02629 |
| Description |
Niraparib is an orally active PARP inhibitor developed by Tesaro to treat ovarian cancer. FDA approval on March 2017. |
| Indications and Usage |
Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XK02 |
| DrugBank ID |
DB11793
|
| KEGG ID |
D10140
|
| MeSH ID |
C545685
|
| PubChem ID |
24958200
|
| TTD Drug ID |
D00BMF
|
| NDC Product Code |
71794-103; 0173-0912; 0173-0915; 11014-0565; 11014-0572; 61876-0723; 0173-0909; 69656-103; 11014-0573; 11014-0571 |
| UNII |
HMC2H89N35
|
| Synonyms |
niraparib | 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide | niraparib hydrochloride | Zejula | MK 4827 | MK4827 | MK-4827 |
